UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-36159 WASHINGTON, D.C. 20549 STEREOTAXIS, INC. FORM 10-Q (Exact name of registrant as specified in its charter) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Indicate by check mark whether the registrant has submitte ...

Stereotaxis, Inc. (NYSE:STXS) Q1 2019 Earnings Conference Call May 9, 2019 9:00 AM ET Company Participants David Fischel - CEO & Chairman Martin Stammer - CFO Conference Call Participants Joshua Jennings - Cowen and Company Operator Good morning. Thank you for joining us for Stereotaxis First Quarter 2019 Earnings Conference Call. Certain statements during the conference call and question-and-answer period to follow may relate to future events, expectations and, as such, constitute forward-looking statement ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS, INC. (Exact name of the Registrant as Specified in its Charter) DELAWARE 94-3120386 (State or Other Jurisdicti ...

Stereotaxis, Inc. (NYSE:STXS) Q4 2018 Earnings Conference Call March 12, 2019 10:00 AM ET Company Representatives David Fischel - Chairman, Chief Executive Officer Marty Stammer - Chief Financial Officer Conference Call Participants Chris Vaster - Private Investor Operator Good morning. Thank you for joining us for the Stereotaxis Fourth Quarter and Full Year 2018 Earnings Conference Call. Certain statements during the conference call and question-and-answer session to follow may relate to future events, ex ...

Investor Presentation 4Q 2018 2 Stereotaxis at a Glance Global Leader in Endovascular Robotics Focused on the Treatment of Cardiac Arrhythmias Extensive Presence 300+ Physicians | 100+ Active Systems | 31 Countries . Validated & Protected 100,000+ Procedures | 300+ Publications | 100+ Issued Patents. Attractive Market $4B+ Existing Market | 10-15% Annual Growth | No Robotic Competitor Financial Highlights* >$30m Sales | >80% Recurring Revenue | >75% Gross Margin . $12.0m Cash and No Debt Enterprise Value ~$ ...